Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | May 01, 2023 | May 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date May 01, 2023 · Filed May 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $342.73 · Expires 2033-04-30 | Direct | 3,481 |
Reported balance
After 2023-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-01 · Grant · Acquired 3,481 · Balance 3,481 F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2019 Filed Jun 4, 2019 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 6,659 | $0.00 Strike: $168.04 | $0.00 |
DisclosureSEC source: 0001209191-19-034233 · doc4.xml · derivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,659 Underlying: Common Stock · 6,659 shares Expires 2029-05-31 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Disposition to issuerCommon Stock | 1,801 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-034233 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,847 F1 · price: Upon the vesting of restricted stock units granted to Mr. Lee on June 1, 2018, Mr. Lee deferred the receipt of 1,801 shares of common stock and received instead 1,801 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Mr. Lee is reporting the disposition of 1,801 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 3,229 | $0.00 Strike: $152.74 | $0.00 |
DisclosureSEC source: 0001209191-18-035747 · doc4.xml · derivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,229 Underlying: Common Stock · 3,229 shares Expires 2028-05-31 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,801 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035747 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,648 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,323 | $128.44 | $169,926.12 |
DisclosureSEC source: 0001209191-17-037907 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,847 F2 · kind: Transaction made pursuant to Mr. Yuchun's company approved trading plan under Rule 10b5-1. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,295 | $0.00 Strike: $125.71 | $0.00 |
DisclosureSEC source: 0001209191-17-037907 · doc4.xml · derivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,295 Underlying: Common Stock · 5,295 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-037907 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,170 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| June 01, 2016 Filed Jun 3, 2016 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 7,073 | $0.00 Strike: $93.51 | $0.00 |
DisclosureSEC source: 0001209191-16-125714 · doc4.xml · derivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,073 Underlying: Common Stock · 7,073 shares Expires 2026-05-31 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2016 Filed Jun 3, 2016 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,941 | $0.01 | $29.41 |
DisclosureSEC source: 0001209191-16-125714 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,982 F1 · shares: Restricted stock unit award that vests on the first anniversary of the grant date. Read SEC document |
| January 04, 2016 Filed Jan 6, 2016 22:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,333 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-16-089929 · doc4.xml · derivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,334 Underlying: Common Stock · 1,333 shares Expires 2022-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 09/14/2012. Read SEC document |
| January 04, 2016 Filed Jan 6, 2016 22:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $122.87 | $24,574.00 |
DisclosureSEC source: 0001209191-16-089929 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,041 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $122.87 (range $122.71 to $123.03). Read SEC document |
| January 04, 2016 Filed Jan 6, 2016 22:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 925 | $122.07 | $112,914.75 |
DisclosureSEC source: 0001209191-16-089929 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,241 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $122.07 (range $121.51 to $122.48). Read SEC document |
| January 04, 2016 Filed Jan 6, 2016 22:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,333 | $57.27 | $76,340.91 |
DisclosureSEC source: 0001209191-16-089929 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2015 Filed Dec 4, 2015 02:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,333 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-15-083422 · doc4.xml · derivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,667 Underlying: Common Stock · 1,333 shares Expires 2022-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 09/14/2012. Read SEC document |
| December 01, 2015 Filed Dec 4, 2015 02:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $131.21 | $13,121.00 |
DisclosureSEC source: 0001209191-15-083422 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 833 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. Read SEC document |
| December 01, 2015 Filed Dec 4, 2015 02:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 625 | $129.97 | $81,231.25 |
DisclosureSEC source: 0001209191-15-083422 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 933 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $129.97 (range $129.64 to $130.60). Read SEC document |
| December 01, 2015 Filed Dec 4, 2015 02:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $128.77 | $51,508.00 |
DisclosureSEC source: 0001209191-15-083422 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,558 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $128.77 (range $128.37 to $129.09). Read SEC document |
| December 01, 2015 Filed Dec 4, 2015 02:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,333 | $57.27 | $76,340.91 |
DisclosureSEC source: 0001209191-15-083422 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2015 Filed Nov 4, 2015 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,334 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-15-078403 · doc4.xml · derivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 1,334 shares Expires 2022-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 09/14/2012. Read SEC document |
| November 02, 2015 Filed Nov 4, 2015 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $126.98 | $63,490.00 |
DisclosureSEC source: 0001209191-15-078403 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $126.98 (range $126.64 to $127.57). Read SEC document |
| November 02, 2015 Filed Nov 4, 2015 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 525 | $125.93 | $66,113.25 |
DisclosureSEC source: 0001209191-15-078403 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,125 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $125.93 (range $125.38 to $126.19). Read SEC document |
| November 02, 2015 Filed Nov 4, 2015 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $123.64 | $12,364.00 |
DisclosureSEC source: 0001209191-15-078403 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 02, 2015 Filed Nov 4, 2015 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,334 | $57.27 | $76,398.18 |
DisclosureSEC source: 0001209191-15-078403 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2015 Filed Oct 6, 2015 00:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,333 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-15-074185 · doc4.xml · derivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,334 Underlying: Common Stock · 1,333 shares Expires 2022-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests in 16 quarterly installments from 09/14/2012. Read SEC document |
| October 01, 2015 Filed Oct 6, 2015 00:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 225 | $105.79 | $23,802.75 |
DisclosureSEC source: 0001209191-15-074185 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416 F1 · shares: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $105.79 (range $105.74 to $105.85). Read SEC document |
| October 01, 2015 Filed Oct 6, 2015 00:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $104.79 | $73,353.00 |
DisclosureSEC source: 0001209191-15-074185 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 641 F1 · shares: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $104.79 (range $104.38 to $105.36). Read SEC document |
| October 01, 2015 Filed Oct 6, 2015 00:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $102.80 | $20,560.00 |
DisclosureSEC source: 0001209191-15-074185 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,341 F1 · shares: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $102.80 (range $102.66 to $102.94). F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2015 Filed Oct 6, 2015 00:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,333 | $57.27 | $76,340.91 |
DisclosureSEC source: 0001209191-15-074185 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. Read SEC document |
| September 01, 2015 Filed Sep 3, 2015 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 1,333 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-15-069493 · doc4.xml · derivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,667 Underlying: Common Stock · 1,333 shares Expires 2022-09-13 F6 · derivative.exercise_date: The option vests in 16 quarterly installments from 9/14/2012. Read SEC document |
| September 01, 2015 Filed Sep 3, 2015 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $126.32 | $25,264.00 |
DisclosureSEC source: 0001209191-15-069493 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $126.32 (range $126.25 to $126.38). Read SEC document |
| September 01, 2015 Filed Sep 3, 2015 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 825 | $125.35 | $103,413.75 |
DisclosureSEC source: 0001209191-15-069493 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $125.35 (range $125.01 to $125.81). Read SEC document |
| September 01, 2015 Filed Sep 3, 2015 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $123.92 | $12,392.00 |
DisclosureSEC source: 0001209191-15-069493 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,233 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $123.92 (range $123.92 to $123.92). Read SEC document |
| September 01, 2015 Filed Sep 3, 2015 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,333 | $57.27 | $76,340.91 |
DisclosureSEC source: 0001209191-15-069493 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 20:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $127.54 | $0.00 |
DisclosureSEC source: 0001209191-15-049602 · doc4.xml · derivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2025-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2014 Filed Jun 3, 2014 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-14-038660 · doc4.xml · derivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2024-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2013 Filed Jun 4, 2013 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $81.54 | $0.00 |
DisclosureSEC source: 0001209191-13-030493 · doc4.xml · derivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2023-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| September 14, 2012 Filed Sep 18, 2012 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-12-045956 · doc4.xml · derivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2022-09-13 F1 · derivative.exercise_date: The option vests in 16 quarterly installments beginning on 12/14/2012. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.